BioSpace News Archive

AbbVie and FutureGen Biopharmaceutical Co., Ltd. announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.

Satsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were selected for presentation at the American Headache Society’s 66th Annual Scientific Meeting.

Incyte Corporation announced the final results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024.

Silq Technologies announced its ClearTract® Foley Catheter has received an Innovative Technology contract from Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company.

Toronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the...

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced the successful completion of patient enrollment for the pancreatic cancer cohort in the Phase 1b/2a CENDIFOX trial.

Aphaia Pharma announced that it has completed enrollment in the second arm of its Phase 2 trial, which is evaluating the safety and efficacy of two separate doses of Aphaia’s formulation, or their respective placebos, twice per day to induce weight loss in individuals with obesity.

Replimune Group, Inc. announced that it has entered into a securities purchase agreement for a private investment in public equity that is expected to result in gross proceeds of approximately $100 million to the Company before deducting placement agent fees and offering expenses.

Asahi Kasei has announced that in April 2024 it began selling a membrane system to produce WFI, a type of sterile water that is used for the preparation of injections.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first healthy volunteers have been dosed in the Phase 1a trial of VYN202.